• About Us
  • Corporate Profile
  • Management Team
  • Board of Directors
  • Scientific Advisory Board
  • Respiratory and Acute Care Advisory Board
  • Cardiovascular Advisory Board
  • Immunology Advisory Board
  • Investors
• Products
• Research
  • sPLA2 - What is it?
  • Respiratory and Acute Care Program
  • sPLA2 in SCD
  • IMPACTS Trial Site
  • Scientific Advisory Board
  • Cardiovascular Program
  • sPLA2 in CVD
  • FRANCIS Trial Site
  • PLASMA Trial Site
  • PLASMA 2 Trial Site
  • Scientific Advisory Board
  • Immunology Program
  • A-623 in SLE and Autoimmune Diseases
  • Scientific Advisory Board
  • Preclinical Programs
  • Glossary
  • References
• News & Media
• Careers
• Contact Us

<< Return to Board of Directors

Paul F. Truex‚ Director

Prior to founding Anthera Pharmaceuticals‚ Mr. Truex served as a Director‚ President and CEO of Peninsula Pharmaceuticals since the commencement of operations in October 2001. During that time‚ Mr. Truex raised over $81‚000‚000 of institutional capital (including $21‚000‚000 from a key strategic partner) and negotiated both of Peninsula's product agreements with Shionogi & Co.‚ Ltd. and Takeda Chemical Industries. Peninsula was acquired by Johnson and Johnson during April of 2005 for $245 Million in an all cash transaction.

Mr. Truex has extensive experience in sales‚ marketing and business development in several industries including pharmaceuticals‚ biotechnology‚ consumer electronics‚ and telecommunications. Prior to Peninsula‚ Mr. Truex was Vice President of Commercial Development for Versicor Inc. (now Vicuron) where he directed early commercial efforts for their infectious disease products and assisted with the company's successful IPO. Prior to joining Versicor‚ Mr. Truex worked at Eli Lilly and Company where he served in various marketing and sales roles during the launch of three different products for the primary care physician market (Actos®‚ Evista®‚ and Humalog 75/25®). His business development experience includes the Lilly ICOS LLC joint venture‚ two major product divestitures and numerous small research collaborations. While there Mr. Truex also worked with several product teams on various divestiture strategies. Mr. Truex is a member of the Board of Directors of InteKrin Therapeutics and Trigemina‚ Inc.

Mr. Truex obtained his M.B.A. in Marketing and Finance from Indiana University and a B.A. Degree in International Economics from the University of Waterloo. Mr. Truex is also a member of the adjunct faculty of California State University‚ Graduate School of Business Administration.